310 related articles for article (PubMed ID: 23338219)
1. Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.
Shlik J; Vasar E; Bradwejn J
CNS Drugs; 1997 Aug; 8(2):134-52. PubMed ID: 23338219
[TBL] [Abstract][Full Text] [Related]
2. Two faces of cholecystokinin: anxiety and schizophrenia.
Bourin M; Malinge M; Vasar E; Bradwejn J
Fundam Clin Pharmacol; 1996; 10(2):116-26. PubMed ID: 8737954
[TBL] [Abstract][Full Text] [Related]
3. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
[TBL] [Abstract][Full Text] [Related]
4. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?
Patel S; Chapman KL; Smith AJ; Bailey I; Freedman SB
Regul Pept; 1996 Aug; 65(1):29-35. PubMed ID: 8876033
[TBL] [Abstract][Full Text] [Related]
5. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.
Charrier D; Dangoumau L; Puech AJ; Hamon M; Thiébot MH
Psychopharmacology (Berl); 1995 Sep; 121(1):127-34. PubMed ID: 8539337
[TBL] [Abstract][Full Text] [Related]
6. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.
Vasar E; Harro J; Lang A; Pôld A; Soosaar A
Psychopharmacology (Berl); 1991; 105(3):393-9. PubMed ID: 1798834
[TBL] [Abstract][Full Text] [Related]
7. Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze.
Kõks S; Soosaar A; Võikar V; Volke V; Ustav M; Männistö PT; Bourin M; Vasar E
Neuropeptides; 1998 Jun; 32(3):235-40. PubMed ID: 10189057
[TBL] [Abstract][Full Text] [Related]
8. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
Crawley JN
J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
[TBL] [Abstract][Full Text] [Related]
9. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.
Chopin P; Briley M
Psychopharmacology (Berl); 1993; 110(4):409-14. PubMed ID: 7870910
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.
Hill DR; Woodruff GN
Brain Res; 1990 Sep; 526(2):276-83. PubMed ID: 2257485
[TBL] [Abstract][Full Text] [Related]
11. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
[TBL] [Abstract][Full Text] [Related]
12. Possible role of cholecystokinin-A receptors in regulation of thyrotropin (TSH) secretion in male rats.
Männistö PT; Peuranen E; Harro J; Vasar E
Neuropeptides; 1992 Dec; 23(4):251-8. PubMed ID: 1475033
[TBL] [Abstract][Full Text] [Related]
13. Presynaptically mediated effects of cholecystokinin-8 on the excitability of area postrema neurons in rat brain slices.
Sugeta S; Hirai Y; Maezawa H; Inoue N; Yamazaki Y; Funahashi M
Brain Res; 2015 Aug; 1618():83-90. PubMed ID: 26005131
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
15. The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats.
Ladurelle N; Keller G; Blommaert A; Roques BP; Daugé V
Eur J Neurosci; 1997 Sep; 9(9):1804-14. PubMed ID: 9383203
[TBL] [Abstract][Full Text] [Related]
16. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
Vasar E; Stephenson JD; Meldrum BS
Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations.
Kõks S; Männistö PT; Bourin M; Shlik J; Vasar V; Vasar E
J Psychiatry Neurosci; 2000 Jan; 25(1):33-42. PubMed ID: 10721682
[TBL] [Abstract][Full Text] [Related]
18. Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism.
Day HE; McKnight AT; Poat JA; Hughes J
Neuropharmacology; 1994 Jun; 33(6):719-27. PubMed ID: 7936109
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.
Ballaz SJ; Bourin M
Curr Neuropharmacol; 2021; 19(7):925-938. PubMed ID: 33185164
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas.
Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z
J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
